Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1CNS 1

Conditions

Medulloblastoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Advanced Fallopian Tube Carcinoma 1

Interventions

pembrolizumab 521Specimen Handling 383Carboplatin 376Magnetic Resonance Spectroscopy 334Cisplatin 331Nivolumab 309Cyclophosphamide 298Radiotherapy 257Paclitaxel 254Biopsy 235Gemcitabine 234Bevacizumab 218Dexamethasone 169durvalumab 167Oxaliplatin 163Capecitabine 159Rituximab 156Fluorouracil 149venetoclax 147Docetaxel 147atezolizumab 143Drug Therapy 143Etoposide 141Doxorubicin 134Ipilimumab 129Prednisone 121Radiosurgery 120Lenalidomide 118Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Diphtheria-Tetanus Vaccine × 1 year × Clear all
NCT05096481 2026-05-11

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Nationwide Children's Hospital

Phase 2 Recruiting
120 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma

NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡